A novel role for carcinoembryonic antigen-related cell adhesion molecule 6 as a determinant of gemcitabine chemoresistance in pancreatic adenocarcinoma cells - PubMed (original) (raw)
A novel role for carcinoembryonic antigen-related cell adhesion molecule 6 as a determinant of gemcitabine chemoresistance in pancreatic adenocarcinoma cells
Mark S Duxbury et al. Cancer Res. 2004.
Abstract
Most patients with pancreatic adenocarcinoma present with surgically incurable disease. Gemcitabine, the principal agent used to treat such patients, has little impact on outcome. Overexpression of carcinoembryonic antigen-related cell adhesion molecule (CEACAM) 6, a feature of this malignancy, is associated with resistance to anoikis and increased metastasis. The purpose of this study was to determine the role of CEACAM6 in cellular chemoresistance to gemcitabine. CEACAM6 was stably overexpressed in Capan2 cells, which inherently express very low levels of the protein. Suppression of CEACAM6 expression was achieved in BxPC3 cells, which inherently overexpress CEACAM6, by stable transfection of a CEACAM6 small interfering RNA-generating vector. The effects of modulating CEACAM6 expression on gemcitabine-induced cytotoxicity were determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide cytotoxicity assay, flow cytometric apoptosis quantification, caspase profiling, and Western analysis of cytoplasmic cytochrome c release. The roles of Akt and c-Src kinases as downstream targets of CEACAM6 signaling were examined. Stable overexpression of CEACAM6 in Capan2 increased gemcitabine chemoresistance, whereas CEACAM6 gene silencing in BxPC3 markedly increased the sensitivity of these cells to gemcitabine. Differential expression of CEACAM6 modulates Akt activity in a c-Src-dependent manner, and CEACAM6 overexpression appears to protect cells from cytochrome c-induced caspase 3 activation and apoptosis.
Similar articles
- Overexpression of CEACAM6 promotes insulin-like growth factor I-induced pancreatic adenocarcinoma cellular invasiveness.
Duxbury MS, Ito H, Benoit E, Zinner MJ, Ashley SW, Whang EE. Duxbury MS, et al. Oncogene. 2004 Jul 29;23(34):5834-42. doi: 10.1038/sj.onc.1207775. Oncogene. 2004. PMID: 15208677 - RNA interference demonstrates a novel role for integrin-linked kinase as a determinant of pancreatic adenocarcinoma cell gemcitabine chemoresistance.
Duxbury MS, Ito H, Benoit E, Waseem T, Ashley SW, Whang EE. Duxbury MS, et al. Clin Cancer Res. 2005 May 1;11(9):3433-8. doi: 10.1158/1078-0432.CCR-04-1510. Clin Cancer Res. 2005. PMID: 15867245 Free PMC article. - CEACAM6 gene silencing impairs anoikis resistance and in vivo metastatic ability of pancreatic adenocarcinoma cells.
Duxbury MS, Ito H, Zinner MJ, Ashley SW, Whang EE. Duxbury MS, et al. Oncogene. 2004 Jan 15;23(2):465-73. doi: 10.1038/sj.onc.1207036. Oncogene. 2004. PMID: 14724575 Retracted. - The emerging roles of CEACAM6 in human cancer (Review).
Wu G, Wang D, Xiong F, Wang Q, Liu W, Chen J, Chen Y. Wu G, et al. Int J Oncol. 2024 Mar;64(3):27. doi: 10.3892/ijo.2024.5615. Epub 2024 Jan 19. Int J Oncol. 2024. PMID: 38240103 Free PMC article. Review. - Gemcitabine chemoresistance in pancreatic cancer: molecular mechanisms and potential solutions.
Andersson R, Aho U, Nilsson BI, Peters GJ, Pastor-Anglada M, Rasch W, Sandvold ML. Andersson R, et al. Scand J Gastroenterol. 2009;44(7):782-6. doi: 10.1080/00365520902745039. Scand J Gastroenterol. 2009. PMID: 19214867 Review.
Cited by
- CEACAM6 expression and function in tumor biology: a comprehensive review.
Zhao D, Cai F, Liu X, Li T, Zhao E, Wang X, Zheng Z. Zhao D, et al. Discov Oncol. 2024 May 25;15(1):186. doi: 10.1007/s12672-024-01053-6. Discov Oncol. 2024. PMID: 38796667 Free PMC article. Review. - Anoikis-related genes as potential prognostic biomarkers in gastric cancer: A multilevel integrative analysis and predictive therapeutic value.
Lin Y, Liu J. Lin Y, et al. IET Syst Biol. 2024 Apr;18(2):41-54. doi: 10.1049/syb2.12088. Epub 2024 Feb 20. IET Syst Biol. 2024. PMID: 38377622 Free PMC article. - Glycogen synthase kinase 3β: the nexus of chemoresistance, invasive capacity, and cancer stemness in pancreatic cancer.
Uehara M, Domoto T, Takenaka S, Takeuchi O, Shimasaki T, Miyashita T, Minamoto T. Uehara M, et al. Cancer Drug Resist. 2024 Jan 31;7:4. doi: 10.20517/cdr.2023.84. eCollection 2024. Cancer Drug Resist. 2024. PMID: 38318525 Free PMC article. Review. - CT109-SN-38, a Novel Antibody-drug Conjugate with Dual Specificity for CEACAM5 and 6, Elicits Potent Killing of Pancreatic Cancer Cells.
Cardenas KCA, Enos CW, Spear MR, Austin DE, Almofeez R, Kortchak S, Pincus L, Guo HB, Dolezal S, Pierce JM, Furth E, Gineste C, Kwon Y, Gelber C. Cardenas KCA, et al. Curr Cancer Drug Targets. 2024;24(7):720-732. doi: 10.2174/0115680096260614231115192343. Curr Cancer Drug Targets. 2024. PMID: 38178674 - Kaposi's sarcoma-associated herpesvirus viral protein kinase augments cell survival.
Wu XJ, Zhang Z, Wong JP, Rivera-Soto R, White MC, Rai AA, Damania B. Wu XJ, et al. Cell Death Dis. 2023 Oct 18;14(10):688. doi: 10.1038/s41419-023-06193-1. Cell Death Dis. 2023. PMID: 37852997 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous